Trial · NCT00588666
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
NCT00588666, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2016-01-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma. Trials, record NCT00588666. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00588666
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
- NCT number
- NCT00588666
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 51 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Myeloproliferative Disorder, Urothelial Carcinoma, Cancer
- Interventions
- Bevacizumab, Carboplatin, Gemcitabine
- First posted
- 2008-01-08
- Last updated
- 2016-01-22
- Results first posted
- 2016-01-22
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate the Time to Disease Progression | 3 years | Response and progression will be evaluated in this study using the international criteria by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee \[JNCI, 92(3):205-216, 2000\]. Changes in only the largest diameter (uni-dimensional measurement) are used in the RECIST criteria. |
| Secondary | The Response Rate of Combination Therapy With Bevacizumab, Gemcitabine, and Carboplatin in Patients With Advanced/Metastatic TCC. | 3 years |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Evaluate the Time to Disease Progression | 3 years | months | MEDIAN | |
| SECONDARY | The Response Rate of Combination Therapy With Bevacizumab, Gemcitabine, and Carboplatin in Patients With Advanced/Metastatic TCC. | 3 years | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Evaluate the Time to Disease Progression | Treatment | Time to Progression | 6.5 | 95% Confidence Interval 4.7 to 7.8 | months |
| Evaluate the Time to Disease Progression | Treatment | Overall Survival | 13.9 | 95% Confidence Interval 11.9 to 18.1 | months |
| The Response Rate of Combination Therapy With Bevacizumab, Gemcitabine, and Carboplatin in Patients With Advanced/Metastatic TCC. | Treatment | 49 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment | 51 | |
| Overall Study | COMPLETED | Treatment | 47 | |
| Overall Study | NOT COMPLETED | Treatment | 4 |
Source ClinicalTrials.gov
Adverse events36
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Treatment | 11 | 51 | 30 |
| other | Nausea | Gastrointestinal disorders | Treatment | 3 | 51 | 6 |
| other | Thrombosis/thrombus/embolism | Vascular disorders | Treatment | 4 | 51 | 4 |
| other | Weight loss | Investigations | Treatment | 4 | 51 | 6 |
| serious | Myocardial ischemia | Cardiac disorders | Treatment | 1 | 51 | 1 |
| serious | Cholecystitis | Hepatobiliary disorders | Treatment | 1 | 51 | 1 |
| serious | Constipation | Gastrointestinal disorders | Treatment | 2 | 51 | 2 |
| serious | Death | General disorders | Treatment | 1 | 51 | 1 |
| serious | Dysphagia | Gastrointestinal disorders | Treatment | 1 | 51 | 1 |
| serious | Fatigue | General disorders | Treatment | 1 | 51 | 1 |
1 to 10 of 36Source ClinicalTrials.gov
See all 36 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment | ||
| Total, other adverse events | Treatment | 15 | 51 |
| Total, serious adverse events | Treatment | 29 | 51 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00588666
GET https://conductscience.org/api/trials/v1/NCT00588666/events?page=2